License Agreement with Yuhan Corporation (Details Narrative) - USD ($) |
Oct. 06, 2020 |
Aug. 19, 2020 |
|---|---|---|
| Subsequent Event [Member] | Underwritten Public Offering [Member] | ||
| Number of common stock issued during period | 4,800,000 | |
| Price per share | $ 4 | |
| Proceeds from offering | $ 17,100,000 | |
| License Agreement [Member] | Yuhan Corporation [Member] | ||
| Common stock, issuance description | As consideration for the Yuhan License Agreement, we issued to Yuhan 250,000 shares of common stock (based upon an $8.00 per share price). Per the Yuhan License Agreement, we will issue an additional 250,000 shares based on the $4.00 per share price in the underwritten public offering, which closed on October 6, 2020. | |
| Number of common stock issued during period | 250,000 | |
| Price per share | $ 8.00 | |
| Milestone payments, description | In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter into. | |
| Performance of milestone conditions, description | Specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product within 48 months. | |
| License Agreement [Member] | Yuhan Corporation [Member] | Underwritten Public Offering [Member] | ||
| Number of common stock issued during period | 750,000 | |
| Proceeds from offering | $ 3,000,000 | |
| License Agreement [Member] | Yuhan Corporation [Member] | Subsequent Event [Member] | ||
| Number of common stock issued during period | 250,000 | |
| Price per share | $ 4.00 |